NSYNC’s Lance Bass shares his journey with type 1.5 diabetes, also known as latent autoimmune diabetes in adults (LADA). The ...

I think the biggest tragedy in all of this is standing by on a billing code and refusing to be human and even reach out to ...

Results from a new study published in Clinical and Translational Immunology found that dual-target antibody therapy can enhance cancer-fighting T cells more effectively than current single-target ...

When blood cancer cells break through the bone and multiply, tumor cells become dangerously diverse and the immune response in the region changes, researchers report. The detailed insights into cancer ...

Approval of Adcetris provides a new treatment option for patients with relapsed or refractory large b-cell lymphoma who are ...

Interrupting signals exchanged between tumors and the nervous system could become a critical pillar of cancer care ...

Leukemia is a leading cause of death among children in India, with over 30,000 cases diagnosed annually. Early diagnosis is ...

Pfizer’s Adcetris combination regimen gets US FDA approval to treat relapsed/refractory diffuse large B-cell lymphoma: New York Friday, February 14, 2025, 11:00 Hrs [IST] Pfizer ...

Organoids were cultured from healthy donor iPSC sources and differentiated using the human iPSC-derived Cerebral Organoid ...

By targeting surface markers on cancer cells, engineered synthetic receptors expressed on immune cells can be directed to ...

Although CAR T-cell therapies have been found effective against certain difficult-to-treat malignancies, they are not devoid of safety concerns.